Physician profile
Rabya Rasheed Mian
NPI 1861608309
$3,405.71
in general payments reported to CMS, 2019-2025
21 companies · $561 in 2025
The $561 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $178 · 2021: $338 · 2022: $624 · 2023: $337 · 2024: $673 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472 · Education: $99.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.74 |
| Education | $99.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $476.67 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $414.91 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $393.72 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $387.26 | 2019-2025 | Dupixent |
| Genzyme Corporation | $348.38 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $324.69 | 2019-2025 | |
| Pfizer INC. | $234.57 | 2019-2025 | |
| Optinose US, INC. | $218.22 | 2019-2025 | |
| Kaleo, INC. | $197.77 | 2019-2024 | Auvi-Q |
| Greer Laboratories, INC. | $70.01 | 2024 | Oralair |
| Ars Pharmaceuticals Operations, INC. | $68.54 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $56.36 | 2019-2020 | |
| Csl Behring | $40.68 | 2025 | Andembry |
| Grifols USA, LLC | $34.11 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $30.61 | 2023 | Ryaltris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $29.83 | 2021 | |
| Cycle Pharmaceuticals INC | $21.09 | 2025 | Sajazir |
| Takeda Pharmaceuticals U.S.A., INC. | $19.87 | 2025 | Cuvitru |
| Phadia US INC. | $19.75 | 2023 | Immunocap |
| Azurity Pharmaceuticals, INC. | $18.00 | 2025 | Alvesco |
| Organon LLC | $0.67 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabya Mian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.